+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antisense and RNAi Therapeutics Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797840
The global antisense and rNAi therapeutics market size attained a value of USD 1.7 billion in 2022. The market is anticipated to grow at a CAGR of 8.5% during the forecast period of 2023-2031 to attain a value of USD 3.56 billion by 2031.

Antisense and RNAi Therapeutics Market: Introduction

Antisense and RNAi (RNA interference) therapeutics are two distinct, yet related, approaches to gene silencing that are used to treat various diseases by modulating the expression of specific genes. Both techniques involve the use of small, synthetic nucleic acid molecules to target and regulate specific messenger RNA (mRNA) molecules, which play a crucial role in the production of proteins.

Antisense Therapeutics:
Antisense therapeutics involves the use of short, single-stranded DNA or RNA molecules called antisense oligonucleotides (ASOs) that are complementary to the target mRNA sequence. When ASOs bind to the target mRNA, they form a double-stranded complex that can inhibit the translation of the mRNA into protein. This process can be achieved through various mechanisms, including:
1. Steric hindrance: The ASO-mRNA complex prevents the ribosome from binding to the mRNA, thereby inhibiting protein synthesis.
2. Recruitment of RNAse H: The ASO-mRNA complex recruits an enzyme called RNAse H, which selectively cleaves and degrades the mRNA.
3. Modulation of alternative splicing: ASOs can bind to specific sites on pre-mRNA, leading to changes in splicing patterns and the production of different protein isoforms.

RNAi Therapeutics:
RNAi therapeutics is based on a naturally occurring cellular mechanism that uses small RNA molecules to regulate gene expression. The two main players in RNAi are small interfering RNAs (siRNAs) and microRNAs (miRNAs). In therapeutic applications, synthetic siRNAs or miRNAs are designed to target specific mRNA molecules for degradation or translational repression.
1. siRNAs: These are double-stranded RNA molecules, typically 21-23 nucleotides in length, that are complementary to the target mRNA sequence. Once introduced into cells, siRNAs are incorporated into the RNA-induced silencing complex (RISC). The RISC then cleaves and unwinds the siRNA, retaining the guide strand, which is complementary to the target mRNA. The guide strand directs the RISC to the target mRNA, leading to its cleavage and degradation, thereby silencing the expression of the corresponding gene.
2. miRNAs: These are single-stranded RNA molecules, approximately 22 nucleotides in length, that are partially complementary to the target mRNA sequence. miRNAs are processed and incorporated into the RISC, like siRNAs. However, due to partial complementarity, miRNAs generally do not induce mRNA cleavage. Instead, they cause translational repression by interfering with ribosome binding or inducing mRNA deadenylation and decay.

3. Both antisense and RNAi therapeutics have shown promise in the treatment of various diseases, including cancer, genetic disorders, and viral infections, by selectively silencing the expression of disease-associated genes.

Antisense And RNAi Therapeutics Market Segmentations

The market can be categorised into technology, indication, route of administration, end user, and region.

Market Breakup by Technology

  • RNA Interference
  • siRNA
  • miRNA
  • Antisense RNA

Market Breakup by Indication

  • Oncology
  • Cardiovascular Disease
  • Respiratory Disorders
  • Renal Disease
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Disease
  • Others

Market Breakup by Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intra-dermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Others

Market Breakup by End User

  • Market Overview
  • Hospitals
  • Specialty Clinics
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Antisense and RNAi Therapeutics Market Scenario

The global antisense and RNAi therapeutics market is experiencing significant growth, driven by the increasing demand for targeted therapies, advancements in gene silencing technologies, and the rising prevalence of chronic diseases, such as cancer, genetic disorders, and viral infections. These therapeutic approaches offer promising potential in the development of personalized treatments and overcoming challenges associated with conventional drug therapies, such as drug resistance and off-target effects.

Market Drivers

Several factors are contributing to the growth of the antisense and RNAi therapeutics market. The escalating prevalence of chronic diseases, coupled with the unmet medical needs for effective treatments, is fuelling the demand for novel therapeutics. Additionally, advancements in molecular biology, genomics, and bioinformatics have led to a better understanding of disease mechanisms and the development of more precise and effective gene silencing therapies. Furthermore, increased investment in research and development by biopharmaceutical companies and government initiatives supporting the development of genetic therapies are propelling market growth.

Market Challenges

Despite the promising potential, the antisense and RNAi therapeutics market faces several challenges. The delivery of these therapeutics to target cells and tissues remains a significant hurdle, with issues such as low cellular uptake, rapid degradation, and potential off-target effects. Furthermore, the high cost of development and stringent regulatory requirements for the approval of genetic therapies may impede market growth. Additionally, the need for extensive preclinical and clinical studies to establish the safety and efficacy of these therapeutics presents both time and financial constraints.

Regional Analysis

The global antisense and RNAi therapeutics market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America leads the market, owing to its well-established biotechnology and pharmaceutical industries, increased investment in research and development, and favourable government policies. Europe follows closely, while the Asia-Pacific region is anticipated to witness the fastest growth rate due to the increasing prevalence of chronic diseases, growing investment in biotechnology, and improving healthcare infrastructure.

Future Outlook

The antisense and RNAi therapeutics market is expected to continue its growth trajectory in the coming years, primarily driven by ongoing advancements in gene silencing technologies, the development of more effective delivery systems, and the increasing adoption of personalized medicine. The successful clinical translation and commercialization of these therapies will further validate their potential, opening new opportunities for the treatment of various diseases, including those with limited or no current therapeutic options.

Key Players in the Global Antisense and RNAi Therapeutics Market

The report gives an in-depth analysis of the key players involved in the antisense and RNAi therapeutics market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • OliX Pharmaceuticals, Inc
  • Sanofi S.A. SAN (EPA)
  • GlaxoSmithKline Plc GSK (LON)
  • Ionis Pharmaceuticals, Inc
  • Benitec Biopharma Inc.,
  • Silence Therapeutics Plc
  • Astellas Pharma Inc
  • Alnylam Pharmaceuticals, Inc
  • Dicerna Pharmaceuticals
  • Tekmira Pharmaceuticals
  • Cenix BioScience
  • Sirnaomics
  • Arrowhead Pharmaceuticals

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Antisense and RNAi Therapeutics Market Overview
3.1 Global Antisense and RNAi Therapeutics Market Historical Value (2016-2022)
3.2 Global Antisense and RNAi Therapeutics Market Forecast Value (2023-2031)
4 Global Antisense and RNAi Therapeutics Market Landscape
4.1 Global Antisense and RNAi Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Antisense and RNAi Therapeutics Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Indication
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by End User
5 Global Antisense and RNAi Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Antisense and RNAi Therapeutics Market Segmentation
6.1 Global Antisense and RNAi Therapeutics Market by Technology
6.1.1 Market Overview
6.1.2 RNA Interference
6.1.3 siRNA
6.1.4 miRNA
6.1.5 Antisense RNA
6.2 Global Antisense and RNAi Therapeutics Market by Indication
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Cardiovascular Disease
6.2.4 Respiratory Disorders
6.2.5 Renal Disease
6.2.6 Neurodegenerative Disorders
6.2.7 Genetic Disorders
6.2.8 Infectious Disease
6.2.9 Others
6.3 Global Antisense and RNAi Therapeutics Market by Route of Administration
6.3.1 Market Overview
6.3.2 Pulmonary Delivery
6.3.3 Intravenous Injections
6.3.4 Intra-dermal Injections
6.3.5 Intraperitoneal Injections
6.3.6 Topical Delivery
6.3.7 Others
6.4 Global Antisense and RNAi Therapeutics Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Specialty Clinics
6.4.4 Others
6.5 Global Antisense and RNAi Therapeutics Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Antisense and RNAi Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Antisense and RNAi Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Antisense and RNAi Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Antisense and RNAi Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Antisense and RNAi Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 OliX Pharmaceuticals, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Sanofi S.A. SAN (EPA)
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 GlaxoSmithKline Plc GSK (LON)
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Ionis Pharmaceuticals, Inc.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Benitec Biopharma Inc.,
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Silence Therapeutics Plc
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Astellas Pharma Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Alnylam Pharmaceuticals, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Dicerna Pharmaceuticals
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Tekmira Pharmaceuticals
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Cenix BioScience
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Sirnaomics
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Arrowhead Pharmaceuticals
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
18 Global Antisense and RNAi Therapeutics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Olix Pharmaceuticals, Inc.
  • Sanofi S.A. San (Epa)
  • GlaxoSmithKline plc Gsk (Lon)
  • Ionis Pharmaceuticals, Inc.
  • Benitec Biopharma Inc.
  • Silence Therapeutics plc
  • Astellas Pharma Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Medline Industries
  • Dicerna Pharmaceuticals
  • Tekmira Pharmaceuticals
  • Cenix Bioscience
  • Sirnaomics
  • Arrowhead Pharmaceuticals



Table Information